| Autoimmune Encephalitis Epidemiology and a Comparison to Infectious Encephalitis |
66 |
| Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts |
53 |
| Deep gray matter volume loss drives disability worsening in multiple sclerosis |
52 |
| Person-Specific Contribution of Neuropathologies to Cognitive Loss in Old Age |
47 |
| Effect of Sleep on Overnight Cerebrospinal Fluid Amyloid beta Kinetics |
44 |
| Inflammatory intrathecal profiles and cortical damage in multiple sclerosis |
43 |
| High complement levels in astrocyte-derived exosomes of Alzheimer disease |
42 |
| Silent progression in disease activity-free relapsing multiple sclerosis |
42 |
| Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes |
40 |
| Age-related changes in the gut microbiota influence systemic inflammation and stroke outcome |
35 |
| Longitudinal tau accumulation and atrophy in aging and alzheimer disease |
33 |
| Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion |
32 |
| Amyloid-beta immunotherapy for alzheimer disease: Is it now a long shot? |
31 |
| Getting the best outcomes from epilepsy surgery |
30 |
| B-Cell Therapy for Multiple Sclerosis: Entering an Era |
29 |
| The impact of amyloid-beta and tau on prospective cognitive decline in older individuals |
28 |
| Ischemic stroke in cancer patients: A review of an underappreciated pathology |
28 |
| A probiotic modulates the microbiome and immunity in multiple sclerosis |
28 |
| Six-Month Assessment of a Hand Prosthesis with Intraneural Tactile Feedback |
28 |
| High-Frequency Oscillations in the Normal Human Brain |
27 |
| Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies |
27 |
| Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein |
27 |
| Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis |
27 |
| Association of Prothrombin Complex Concentrate Administration and Hematoma Enlargement in Non-Vitamin K Antagonist Oral Anticoagulant-Related Intracerebral Hemorrhage |
27 |
| Age of first exposure to tackle football and chronic traumatic encephalopathy |
26 |
| Early electroencephalography for outcome prediction of postanoxic coma: A prospective cohort study |
26 |
| N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E-2 to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice |
25 |
| A Prospective Trial of Magnetic Resonance-Guided Focused Ultrasound Thalamotomy for Essential Tremor: Results at the 2-Year Follow-up |
25 |
| Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease |
25 |
| Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies |
24 |
| Stereotactic laser amygdalohippocampotomy for mesial temporal lobe epilepsy |
24 |
| Oligonucleotide therapy mitigates disease in spinocerebellar ataxia type 3 mice |
24 |
| Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation |
24 |
| Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke |
23 |
| Seeding variability of different alpha synuclein strains in synucleinopathies |
23 |
| GGC Repeat Expansion of NOTCH2NLC in Adult Patients with Leukoencephalopathy |
22 |
| A randomized study of solriamfetol for excessive sleepiness in narcolepsy |
22 |
| Glymphatics Visualization after Focused Ultrasound-Induced Blood-Brain Barrier Opening in Humans |
22 |
| Genetic predisposition in anti-LGI1 and anti-NMDA receptor encephalitis |
21 |
| Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy |
21 |
| Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease |
21 |
| Tocilizumab treatment for new onset refractory status epilepticus |
21 |
| High-Frequency Oscillations Are Not Better Biomarkers of Epileptogenic Tissues Than Spikes |
21 |
| Diabetic neuropathy differs between type 1 and type 2 diabetes: Insights from magnetic resonance neurography |
21 |
| Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies |
20 |
| Prevalence of amyloid-beta pathology in distinct variants of primary progressive aphasia |
20 |
| Prodromal symptoms of multiple sclerosis in primary care |
19 |
| Meningeal inflammation and cortical demyelination in acute multiple sclerosis |
19 |
| Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease |
19 |
| Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis |
18 |
